Clinical Trials Using Gefitinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Gefitinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
Location: 6 locations
Osimertinib and Gefitinib in Treating Patients with EGFR Mutant Stage IV Non-small Cell Lung cancer
This randomized phase I / II trial studies the side effects and best dose of osimertinib when given together with gefitinib in treating patients with EGFR mutant stage IV non-small cell lung cancer. Osimertinib and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 3 locations
Gefitinib in Treating Patients With Newly Diagnosed Liver Cancer That Can Be Removed By Surgery
This pilot early phase I trial studies gefitinib in treating patients with newly diagnosed liver cancer that can be removed by surgery. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland
Nazartinib and Gefitinib in Treating Patients with Recurrent or Stage IIIB-IV EGFR-Mutant Non-small Cell Lung Cancer
This phase II trial studies how well nazartinib and gefitinib work in treating patients with EGFR-mutant non-small cell lung cancer that has come back or is stage IIIB-IV. Nazartinib and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts